In the past week, Moderna presented updated clinical data for its mRNA-4359 cancer vaccine at the 2025 ESMO Congress in Berlin, showing a 24% objective response rate and promising results in PD-L1+ ...
Source LinkIn the past week, Moderna presented updated clinical data for its mRNA-4359 cancer vaccine at the 2025 ESMO Congress in Berlin, showing a 24% objective response rate and promising results in PD-L1+ ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.